We also have some biopharmaceutical companies that have transferred all their R and D all to Germany because they thought it was advantageous.
The point we're making is that with the dollar exchange having changed so dramatically in a short period of time, it's very hard for us to adjust.
The other point is that it's very hard to make business decisions when you're told that you can get some investment tax credits, but it turns out that once you invest and then try to claim the tax credit, you cannot make this into real money because they postpone it year after year.
We acknowledge that the federal government has made an important step in increasing the time to claim those credits from 10 to 20 years, but it has to be available at some point. As you know, and as we said, when you're negotiating with companies who have a choice of investing in Canada, the U.S.A., India, or anywhere else around the world now, they look at how much it will represent on the bottom line.
It used to be a lot more positive when our dollar was stronger, but now we are in a deficit situation and it's hurting R and D. This is why we're asking the government to make this into more monetary terms, instead of just against tax credits. It can be against other taxes that we pay. We're just suggesting that the government see a possibility to help the R and D companies that want to continue doing R and D in Canada.